In conclusion, our results demonstrate that since a state of high proliferation and metabolic activity is a hallmark of cancer, therapeutic strategies that disrupt the mTORC2–TMBIM6 interaction and/or inhibit TMBIM6 expression may be effective in the treatment of cancers characterized by AKT activation. Here, TMBIM6 is linked to cancer.